NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia
October 08 2024 - 8:10AM
Business Wire
New test fills unmet need for faster AML
biomarker testing, expanding NeoGenomics’ broad oncology testing
portfolio
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology
testing services company, announced today the launch of AML
Express, a next-generation sequencing (NGS) assay designed to
provide rapid, comprehensive genetic profiling for patients with
acute myeloid leukemia (AML).
“AML Express enhances our hematologic portfolio by addressing
the clinical need for faster testing that informs critical
treatment decisions,” said Chris Smith, CEO of NeoGenomics. “This
new test offers physicians a more efficient solution that delivers
patient-specific insights to guide precise treatment
strategies.”
AML accounts for about 1 out of 3 leukemias in adults. It is an
aggressive disease that often develops and progresses rapidly over
a few weeks, making access to timely and accurate diagnostic and
prognostic information critical for patient care. With a turnaround
time of just three to four days, AML Express delivers a time- and
cost-effective alternative to traditional single-gene testing
methods.
The panel includes an extensive list of genes selected for their
clinical relevance in AML, covering DNA and RNA alterations, and is
intended to be used in conjunction with clinical features and other
laboratory results. AML Express simplifies the decision-making
process for clinicians, facilitates patient enrollment in clinical
trials, and supports the development of personalized treatment
strategies.
“Patients with newly diagnosed acute myeloid leukemia are
extremely ill at diagnosis and are at risk of life-threatening
complications before initiating treatment,” said Dr. Nathan
Montgomery, Vice President of Medical Services at NeoGenomics. “AML
Express will be an important tool to help patients get the right
treatment sooner, which we believe will reduce the length of
hospital stays and improve patient outcomes."
AML Express aligns with the latest guidelines from the European
LeukemiaNet, adopted by the National Comprehensive Cancer Network
(NCCN), and the World Health Organization Classification for
Hematolymphoid Tumors (5th edition). The new panel expands
NeoGenomics' broad hematology portfolio, which includes Neo
Comprehensive NGS tests, COMPASS®, and other key assays.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and
information services, providing one of the most comprehensive
oncology-focused testing menus for physicians to help them diagnose
and treat cancer. The Company's Advanced Diagnostic Division also
serves pharmaceutical clients in clinical trials and drug
development.
Headquartered in Fort Myers, FL, NeoGenomics operates
CAP-accredited and CLIA-certified laboratories for full-service
sample processing in Fort Myers, Florida; Aliso Viejo and San
Diego, California; Research Triangle Park, North Carolina; and
Houston, Texas; and a CAP-accredited full-service,
sample-processing laboratory in Cambridge, United Kingdom.
NeoGenomics also has several, small, non-processing laboratory
locations across the United States for providing analysis services.
NeoGenomics serves the needs of pathologists, oncologists, academic
centers, hospital systems, pharmaceutical firms, integrated service
delivery networks, and managed care organizations throughout the
United States, and pharmaceutical firms in Europe and Asia.
Forward-Looking Statements
This press release includes forward-looking statements. These
forward-looking statements generally can be identified by the use
of words such as “anticipate,” “expect,” “plan,” “could,” “would,”
“may,” “will,” “believe,” “estimate,” “forecast,” “goal,”
“project,” “guidance,” “plan,” “potential” and other words of
similar meaning, although not all forward-looking statements
include these words. This press release includes forward-looking
statements. These forward-looking statements address various
matters, including statements regarding improving operational
efficiency, returning to profitable growth and its ongoing
executive recruitment process. Each forward-looking statement
contained in this press release is subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statement. Applicable risks
and uncertainties include, among others, the Company's ability to
identify and implement appropriate financial and operational
initiatives to improve performance, to identify and recruit
executive candidates, to continue gaining new customers, offer new
types of tests, integrate its acquisitions and otherwise implement
its business plan, and the risks identified under the heading "Risk
Factors" contained in the Company's Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q and the Company's other filings with
the Securities and Exchange Commission.
We caution investors not to place undue reliance on the
forward-looking statements contained in this press release. You are
encouraged to read our filings with the SEC, available at
www.sec.gov, for a discussion of these and other risks and
uncertainties. The forward-looking statements in this press release
speak only as of the date of this document (unless another date is
indicated), and we undertake no obligation to update or revise any
of these statements. Our business is subject to substantial risks
and uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241008921520/en/
Investor Contact Kendra Sweeney
kendra.sweeney@neogenomics.com
Media Contact Andrea Sampson
asampson@sampsonprgroup.com
NeoGenomics (NASDAQ:NEO)
Historical Stock Chart
From Nov 2024 to Dec 2024
NeoGenomics (NASDAQ:NEO)
Historical Stock Chart
From Dec 2023 to Dec 2024